Abnormal GABAergic function and negative affect in schizophrenia

Neuropsychopharmacology

Volumn 39, Issue 4, 2014, Pages 1000-1008

  Taylor, Stephan F ^a   Demeter, Elise ^b   Phan, K Luan ^c   Tso, Ivy F ^d   Welsh, Robert C ^e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

benzodiazepine; emotion; fMRI; psychosis

Indexed keywords

ADULT; CEREBRAL CORTEX; CROSS-OVER STUDIES; FEMALE; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LORAZEPAM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOOD DISORDERS; OXYGEN; PHOTIC STIMULATION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SINGLE-BLIND METHOD; VISUAL PERCEPTION;

EID: 84894081009     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.300     Document Type: Article

References (51)

1. Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM et al (1999). No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 20: 650-661.
2. Addington D, Addington J, Maticka-Tyndale E (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 163: 39-44.
3. Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC (2011). Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 36: 677-683.
4. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th edn. (DSM-IV) American Psychiatric Association: Washington, DC, USA.
5. Amodio DM, Frith CD (2006). Meeting of minds: the medial frontal cortex and social cognition. Nat Rev Neurosci 7: 268-277.
6. Andreasen NC (1983). The scale for the Assessment of Negative Symptoms. The University of Iowa: Iowa City.
7. Bartos M, Vida I, Jonas P (2007). Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci 8: 45-56.
8. Carpenter WT Jr., Buchanan RW, Kirkpatrick B, Breier AF (1999). Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 156: 299-303.
9. Cohen AS, Minor KS (2010). Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull 36: 143-150.
10. Cohen S, Kamarck T, Mermelstein R (1983). A global measure of perceived stress. J Health Soc Behav 24: 385-396.
11. Cousins DA, Young AH (2007). The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol 10: 411-431.
12. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S (2002). Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry 59: 347-354.
13. Etkin A, Egner T, Kalisch R (2011). Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 15: 85-93.
14. First MB, Spitzer RL, Gibbon M, Williams J (1995). Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), ver 2.0. Biometrics Research: New York, USA.
15. Fredrickson BL, Tugade MM, Waugh CE, Larkin GR (2003). What good are positive emotions in crises? A prospective study of resilience and emotions following the terrorist attacks on the United States on September 11th, 2001. J Pers Soc Psychol 84: 365-376.
16. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR et al (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57: 1061-1069.
17. Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW et al (2008a). Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13: 147-161.
18. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA (2008b). Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165: 479-489.
19. Hollingshead AB, Redlich FC (1958). Social class and mental illness. Am J Psychiatry 149: 1035-1044.
20. HoranWP, Blanchard JJ, Clark LA, Green MF (2008). Affective traits in schizophrenia and schizotypy. Schizophr Bull 34: 856-874.
21. Jastak S, Wilkinson GS (1984). Wide Range Achievement Test - Revised. Jastak Associates, Inc.: Wilmington, DE, USA.
22. Jenkinson M, Bannister P, Brady M, Smith S (2002). Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17: 825-841.
23. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004). The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68: 283-297.
24. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al (2012). Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69: 449-459.
25. Kober H, Barrett LF, Joseph J, Bliss-Moreau E, Lindquist K, Wager TD (2008). Functional grouping and cortical-subcortical interactions in emotion: a meta-analysis of neuroimaging studies. Neuroimage 42: 998-1031.
26. Kring AM, Moran EK (2008). Emotional response deficits in schizophrenia: insights from affective science. Schizophr Bull 34: 819-834.
27. Lewis DA, Curley AA, Glausier JR, Volk DW (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35: 57-67.
28. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P et al (2007). Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 64: 156-167.
29. Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S et al (2012). GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62: 1574-1583.
30. Olsen RW, Tobin AJ (1990). Molecular biology of GABAA receptors. Faseb J 4: 1469-1480.
31. Overall JE, Gorham DR (1962). Brief psychiatric rating scale. Psychol Rep 10: 799-812.
32. Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB (2005). Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry 62: 282-288.
33. Phillips LK, Seidman LJ (2008). Emotion processing in persons at risk for schizophrenia. Schizophr Bull 34: 888-903.
34. Qin P, Duncan NW, Wiebking C, Gravel P, Lyttelton O, Hayes DJ et al (2012). GABA(A) receptors in visual and auditory cortex and neural activity changes during basic visual stimulation. Front Hum Neurosci 6: 337.
35. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983). Manual for the State-Trait Anxiety Inventory (Form Y). Mind Garden: Palo Alto, CA, USA.
36. Szabadics J, Varga C, Molnar G, Olah S, Barzo P, Tamas G (2006). Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science 311: 233-235.
37. Taylor SF, Chen AC, Tso IF, Liberzon I, Welsh RC (2011). Social appraisal in chronic psychosis: role of medial frontal and occipital networks. J Psychiatr Res 45: 526-538.
38. Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD (2012). Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry 71: 136-145.
39. Taylor SF, Welsh RC, Chen AC, Velander AJ, Liberzon I (2007). Medial frontal hyperactivity in reality distortion. Biol Psychiatry 61: 1171-1178.
40. Tso IF, Grove TB, Taylor SF (2010). Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia. Schizophr Res 122: 156-163.
41. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al (2002). Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
42. van Rossum I, Dominguez MD, Lieb R, Wittchen HU, van Os J (2011). Affective dysregulation and reality distortion: a 10-year prospective study of their association and clinical relevance. Schizophr Bull 37: 561-571.
43. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA (2002). Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12: 1063-1070.
44. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ 3rd et al (1999). Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 19: 222-232.
45. Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC (2001). Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 41: 1225-1231.
46. Wise RG, Lujan BJ, Schweinhardt P, Peskett GD, Rogers R, Tracey I (2007). The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI. Magn Reson Imaging 25: 801-810.
47. Woodruff A, Xu Q, Anderson SA, Yuste R (2009). Depolarizing effect of neocortical chandelier neurons. Front Neural Circuits 3: 15.
48. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667.
49. Worsley KJ, Friston KJ (1995). Analysis of fMRI time-series revisited-again. Neuroimage 2: 173-181.
50. Yang Y, Gu H, Zhan W, Xu S, Silbersweig D, Stern E (2002). Simultaneous perfusion and BOLD imaging using reverse spiral scanning at 3T: characterization of functional contrast and susceptibility artifacts. Magn Reson Med 48: 278-289.
51. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Ragland JD et al (2010). GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 30: 3777-3781.